NYSE · CIK 0000759866
JHS JOHN HANCOCK INCOME SECURITIES TRUST
Insider trading from SEC Form 4. Last filing Apr 11, 2025. Close $10.17 on Oct 9, 2026, +1% from the 52-week low and -10% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
3
with a Form 4 at this company
Price and insider trades, last year
JHSOct 9, 2026 · close 10.17
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at JOHN HANCOCK INCOME SECURITIES TRUST, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | Thomas Rowe Wright director buy | $11k 1,030 shares | - | 0% from low-5% from high | |
| 16Weak | William K Bacic other buy | $10k 911 shares | - | - | |
| 18Weak | Noni Ellison McKee other buy | $11k 980 shares | +89% | - |
Transactions
The last 4 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 10, 2025 | Thomas Rowe Wright director | POpen-market purchase Common Shares of Beneficial Interest | +1,030 | $10.90 | $11k | 1,030 | Apr 11, 2025 |
| Jan 14, 2025 | William K Bacic other | POpen-market purchase common shares of beneficial interest | +911 | $11.05 | $10k | 911 | Jan 15, 2025 |
| Dec 23, 2024 | Noni Ellison McKee other | POpen-market purchase Common Shares of Beneficial Interest | +880 | $11.53 | $10k | 1,983 | Dec 26, 2024 |
| Dec 23, 2024 | Noni Ellison McKee other | POpen-market purchase Common Shares of Beneficial Interest | +100 | $11.55 | $1,155 | 2,083 | Dec 26, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- William K Bacicother
- Noni Ellison McKeeother, officer
- Thomas Rowe Wrightdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.